Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Acquisitions & Divestments: 2013-2024

Historic Change in Acquisitions & Divestments for Ultragenyx Pharmaceutical (RARE) over the last 12 years, with Dec 2024 value amounting to $410.0 million.

  • Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments rose 44.90% to $135.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $481.2 million, marking a year-over-year increase of 19.13%. This contributed to the annual value of $410.0 million for FY2024, which is 41.05% down from last year.
  • According to the latest figures from FY2024, Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments is $410.0 million, which was down 41.05% from $695.5 million recorded in FY2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments peaked at $718.1 million during FY2021, and registered a low of $410.0 million during FY2024.
  • For the 3-year period, Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments averaged around $518.8 million, with its median value being $450.7 million (2022).
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments soared by 54.32% in 2023 and then crashed by 41.05% in 2024.
  • Yearly analysis of 5 years shows Ultragenyx Pharmaceutical's Change in Acquisitions & Divestments stood at $589.8 million in 2020, then increased by 21.75% to $718.1 million in 2021, then crashed by 37.24% to $450.7 million in 2022, then spiked by 54.32% to $695.5 million in 2023, then slumped by 41.05% to $410.0 million in 2024.